Lakeshore Biopharma Co. Ltd. (LSB)
NASDAQ (CM) NASDAQ (CM) Primary Summary
LSB Chart
LSB Industries, Inc. Appoints Riccardo Bertocco as an Independent Member of the Board of Directors
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB” or the “Company”), today announced that it has appointed Riccardo Bertocco as an independent member of the Board of Directors (“the Board”) of the Company effective April 9, 2025. Mr. Bertocco will stand for direct election by shareholders for the first time at the annual meeting of stockholders on May 15, 2025 (the “2025 Annual Meeting”). Mr. Bertocco has worked extensively in management consulting for more than 25 years,.
LSB Industries, Inc. Reports Operating Results for the 2024 Fourth Quarter and Full Year and Provides Product Sales Volume Outlook for 2025
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB,” “we,” “us,” “our,” or the “Company”) today announced results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Results and Recent Highlights Net sales of $134.9 million compared to $132.6 million in the fourth quarter of 2023 Net loss of $9.1 million compared to a net loss of $5.3 million in the fourth quarter of 2023; the fourth quarter 2024 net loss included approximately $17.1 million of.
LSB Industries, Inc. Schedules 2024 Fourth Quarter and Full Year Financial Results Release for Wednesday, February 26th and Conference Call for Thursday, February 27th
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”) (NYSE: LXU), today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, February 26, 2025 after the close of the stock market. LSB's management will host a conference call on Thursday, February 27, 2025 at 10:00 am ET / 9:00 am CT to discuss these results. Participating in the call will be Chairman, President & Chief Executive Officer, Mark Behrman, Executi.
Lakeshore Biopharma Co. Ltd. Dividends
Lakeshore Biopharma Co. Ltd. Earnings
| 18 Aug 2025 (71 Days) Date | | - Cons. EPS | - EPS |
| 18 Aug 2025 (71 Days) Date | | - Cons. EPS | - EPS |
Lakeshore Biopharma Co. Ltd. (LSB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Lakeshore Biopharma Co. Ltd. ever had a stock split?
Lakeshore Biopharma Co. Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Wang Xu CEO | NASDAQ (CM) Exchange | KYG9845F1090 ISIN |
| CN Country | 758 Employees | - Last Dividend | 4 Oct 2024 Last Split | 16 Mar 2023 IPO Date |
Overview
LakeShore Biopharma Co., Ltd is a forward-looking biopharmaceutical entity committed to the research, development, production, and sale of vaccines and therapeutic biologics targeting infectious diseases and cancer. Born from its predecessor, YS Biopharma Co., Ltd., LakeShore Biopharma transitioned its name in May 2024, a move reflecting its evolution and expanded vision. Established in 2002 and headquartered in Beijing, China, the company exercises a global footprint through its operations in China, the United States, Singapore, the United Arab Emirates, and the Philippines. At its core, LakeShore Biopharma is pioneering through its proprietary PIKA immunomodulating technology platform, a testament to its innovative direction in the biopharmaceutical industry.
Products and Services
- PIKA Rabies Vaccine
- PIKA Recombinant COVID-19 Vaccine
- PIKA YS-ON-001
A groundbreaking vaccine leveraging the PIKA technology platform, this product represents a significant advancement in the prevention of rabies, a critical public health issue worldwide. The PIKA rabies vaccine is designed to offer enhanced immunogenicity and safety, targeting a wide demographic with its innovative approach to rabies vaccination.
In response to the global pandemic, LakeShore Biopharma developed the PIKA recombinant COVID-19 vaccine, utilizing its novel PIKA platform to provide a potentially more efficacious and safer alternative to existing COVID-19 vaccines. This product underscores the company's agility and commitment to addressing emergent global health crises through cutting-edge biotechnological advancements.
Expanding its portfolio into the realm of cancer therapy, LakeShore Biopharma's PIKA YS-ON-001 is a testament to the company's innovative application of its PIKA platform beyond infectious diseases. This therapeutic biologic is aimed at harnessing the body's immune response to target and combat various forms of cancer, illustrating LakeShore Biopharma's ambitious endeavor into oncology.
Contact Information
